Get the Stockscreener App
1.69
17.36%
0.25
Macrogenics Inc stock is traded at $1.69, with a volume of 1.50M.
It is up +17.36% in the last 24 hours and up +9.74% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.44
Open:
$1.51
24h Volume:
1.50M
Relative Volume:
1.28
Market Cap:
$106.62M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.0696
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
+6.96%
1M Performance:
+9.74%
6M Performance:
-38.77%
1Y Performance:
-49.25%
1-Day Range:
$1.51
$1.70
1-Week Range:
$1.44
$1.70
52-Week Range:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.69 | 96.07M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Technical Models Detect Momentum Build in MacroGenics Inc.July 2025 Reactions & Stock Portfolio Risk Control - classian.co.kr
Elliott Wave Theory Predicts Pullback in MacroGenics Inc.July 2025 Outlook & Consistent Growth Equity Picks - classian.co.kr
MacroGenics Inc. Breakout Confirmed by Volume MetricsPortfolio Return Report & AI Driven Stock Movement Reports - thegnnews.com
DC InnoMacroGenics strikes potential $1.7B deal with Gilead | Quantum Computing is expanding - The Business Journals
Is it too late to sell MacroGenics Inc.Earnings Growth Summary & Weekly Chart Analysis and Guides - Newser
What to expect from MacroGenics Inc. in the next 30 daysEarnings Risk Report & Consistent Profit Focused Trading Strategies - Newser
Can MacroGenics Inc. grow without dilution2025 Growth vs Value & Verified Short-Term Trading Plans - thegnnews.com
MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
What candlestick patterns are forming on MacroGenics Inc.Gap Up & Risk Controlled Stock Alerts - Newser
What the charts say about MacroGenics Inc. todayWeekly Trade Analysis & Reliable Entry Point Alerts - Newser
Is MacroGenics Inc. stock ready for a breakoutJuly 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Is now a turning point for MacroGenics Inc.Quarterly Portfolio Summary & Low Volatility Stock Recommendations - Newser
Leerink Partners Has Lowered Expectations for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World
Will MacroGenics Inc. see short term momentumMarket Activity Summary & Consistent Profit Focused Trading Strategies - Newser
Why MacroGenics Inc. stock attracts strong analyst attention2025 Stock Rankings & Real-Time Chart Pattern Alerts - Newser
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates - MSN
MacroGenics price target lowered to $5 from $8 at Leerink - MSN
Rockville’s MacroGenics Appoints New President/CEO For First Time in 24 Years - The MoCo Show -
MacroGenics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
How MacroGenics Inc. stock performs during market volatilityEarnings Beat & Community Supported Trade Ideas - Newser
Macrogenics, Inc. shares fall 1.27% after-hours following Johnson & Johnson's presentation at BofA Securities 2025. - AInvest
MacroGenics appoints Eric Risser as CEO as Scott Koenig exits - The Business Journals
Macrogenics: Leerink Partners lowers PT to $5, maintains Outperform rating. - AInvest
MacroGenics' CEO Transition and Lorigerlimab Trial Uncertainty Warrant Hold Rating Amid Partnership Exploration - AInvest
MacroGenics Price Target Lowered to $5 at Leerink - AInvest
MacroGenics Inc. Reports Q2 2025 Financial Results - MSN
Macrogenics 2025 Q2 Earnings Narrowed Losses and Strong Revenue Growth - AInvest
MacroGenics stock maintains Market Perform rating at Citizens JMP By Investing.com - Investing.com Canada
MacroGenics: Q2 Earnings Snapshot - Greenwich Time
MacroGenics (MGNX): Strategic Transition, Pipeline Progress, and Liquidity Outlook for Biotech Investors - AInvest
Macrogenics Inc (MGNX) Q2 2025 Earnings: EPS of -$0.57 Beats Est - GuruFocus
MacroGenics appoints new CEO - MSN
MacroGenics Slows Its Losses And Adds $70 Million To The Bank - Finimize
MacroGenics reports Q2 EPS (57c), consensus (38c) - TipRanks
MacroGenics Revenue Doubles in Q2 - The Globe and Mail
MacroGenics Appoints Eric Risser as New CEO - The Globe and Mail
MacroGenics Inc earnings missed by $0.11, revenue fell short of estimates - Investing.com Nigeria
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities - GlobeNewswire
MacroGenics Reports Q2 2025 Financials, Updates Key Strategic Priorities - AInvest
MacroGenics Extends Cash Runway to 2027 with $70M Royalty Deal as New CEO Unveils Strategic Roadmap - Stock Titan
MacroGenics Inc. Approaches Psychological Resistance LevelJuly 2025 Volume & Advanced Swing Trade Entry Alerts - classian.co.kr
MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors? - TipRanks
MacroGenics promotes Eric Risser to president and CEO - The Pharma Letter
MacroGenics' Leadership Transition: A Strategic Inflection Point for Capital Efficiency and Growth - AInvest
Short Term Charts Align With Long Term Uptrend in MacroGenics Inc.July 2025 Intraday Action & Weekly Market Pulse Updates - beatles.ru
MacroGenics Appoints Eric Risser As CEO - MarketScreener
MacroGenics names Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Nigeria
MacroGenics appoints Eric Risser as new CEO, succeeding Scott Koenig By Investing.com - Investing.com Nigeria
MacroGenics names Eric Risser as new CEO, succeeding Scott Koenig - Investing.com India
MacroGenics Appoints Eric Risser as President and Chief Executive Officer | MGNX Stock News - GuruFocus
MacroGenics appoints Eric Risser as new CEO, succeeding Scott Koenig - Investing.com
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Macrogenics Inc Stock (MGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):